Annual CFO
-$216.57 M
-$23.03 M-11.90%
December 31, 2023
Summary
- As of February 6, 2025, RVNC annual cash flow from operations is -$216.57 million, with the most recent change of -$23.03 million (-11.90%) on December 31, 2023.
- During the last 3 years, RVNC annual CFO has fallen by -$38.07 million (-21.33%).
- RVNC annual CFO is now -662.24% below its all-time high of -$28.41 million, reached on December 31, 2011.
Performance
RVNC Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$41.09 M
+$38.00 K+0.09%
September 30, 2024
Summary
- As of February 6, 2025, RVNC quarterly cash flow from operations is -$41.09 million, with the most recent change of +$38.00 thousand (+0.09%) on September 30, 2024.
- Over the past year, RVNC quarterly CFO has increased by +$9.87 million (+19.37%).
- RVNC quarterly CFO is now -534.79% below its all-time high of -$6.47 million, reached on September 30, 2013.
Performance
RVNC Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$190.89 M
+$9.87 M+4.92%
September 30, 2024
Summary
- As of February 6, 2025, RVNC TTM cash flow from operations is -$190.89 million, with the most recent change of +$9.87 million (+4.92%) on September 30, 2024.
- Over the past year, RVNC TTM CFO has increased by +$13.14 million (+6.44%).
- RVNC TTM CFO is now -2799.71% below its all-time high of -$6.58 million, reached on March 31, 2013.
Performance
RVNC TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
RVNC Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -11.9% | +19.4% | +6.4% |
| 3 y3 years | -21.3% | +22.7% | +20.2% |
| 5 y5 years | -107.8% | -28.6% | -79.8% |
RVNC Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -11.9% | +2.2% | -36.1% | +40.9% | at high | +13.8% |
| 5 y | 5-year | -104.0% | +2.2% | -138.7% | +45.0% | -79.8% | +21.0% |
| alltime | all time | -662.2% | +2.2% | -534.8% | +45.0% | -2799.7% | +21.0% |
Revance Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$41.09 M(-0.1%) | -$190.89 M(-4.9%) |
| Jun 2024 | - | -$41.13 M(-37.6%) | -$200.76 M(-5.8%) |
| Mar 2024 | - | -$65.94 M(+54.3%) | -$213.01 M(-1.6%) |
| Dec 2023 | -$216.57 M(+11.9%) | -$42.73 M(-16.2%) | -$216.57 M(+6.2%) |
| Sep 2023 | - | -$50.96 M(-4.5%) | -$204.03 M(-3.3%) |
| Jun 2023 | - | -$53.38 M(-23.2%) | -$210.94 M(+4.5%) |
| Mar 2023 | - | -$69.50 M(+130.3%) | -$201.78 M(+4.3%) |
| Dec 2022 | -$193.55 M(-12.6%) | -$30.18 M(-47.8%) | -$193.55 M(-6.9%) |
| Sep 2022 | - | -$57.87 M(+30.9%) | -$207.98 M(+2.3%) |
| Jun 2022 | - | -$44.23 M(-27.8%) | -$203.27 M(-2.3%) |
| Mar 2022 | - | -$61.27 M(+37.3%) | -$208.05 M(-6.1%) |
| Dec 2021 | -$221.54 M(+24.1%) | -$44.61 M(-16.1%) | -$221.54 M(-7.4%) |
| Sep 2021 | - | -$53.17 M(+8.5%) | -$239.24 M(-1.0%) |
| Jun 2021 | - | -$49.01 M(-34.4%) | -$241.76 M(+15.1%) |
| Mar 2021 | - | -$74.75 M(+20.0%) | -$209.97 M(+17.6%) |
| Dec 2020 | -$178.50 M(+68.1%) | -$62.31 M(+11.9%) | -$178.50 M(+19.2%) |
| Sep 2020 | - | -$55.69 M(+223.5%) | -$149.70 M(+18.8%) |
| Jun 2020 | - | -$17.21 M(-60.2%) | -$125.96 M(-8.7%) |
| Mar 2020 | - | -$43.29 M(+29.2%) | -$138.04 M(+30.0%) |
| Dec 2019 | -$106.16 M(+1.8%) | -$33.51 M(+4.9%) | -$106.16 M(+2.3%) |
| Sep 2019 | - | -$31.95 M(+9.1%) | -$103.79 M(+6.7%) |
| Jun 2019 | - | -$29.29 M(+156.6%) | -$97.25 M(-7.0%) |
| Mar 2019 | - | -$11.41 M(-63.3%) | -$104.52 M(+0.3%) |
| Dec 2018 | -$104.25 M | -$31.14 M(+22.6%) | -$104.25 M(+2.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$25.40 M(-30.5%) | -$101.50 M(+4.0%) |
| Jun 2018 | - | -$36.56 M(+228.0%) | -$97.56 M(+14.4%) |
| Mar 2018 | - | -$11.14 M(-60.8%) | -$85.29 M(-10.5%) |
| Dec 2017 | -$95.34 M(+59.4%) | -$28.40 M(+32.3%) | -$95.34 M(+18.6%) |
| Sep 2017 | - | -$21.46 M(-11.6%) | -$80.41 M(+9.7%) |
| Jun 2017 | - | -$24.29 M(+14.6%) | -$73.30 M(+12.2%) |
| Mar 2017 | - | -$21.19 M(+57.4%) | -$65.34 M(+9.2%) |
| Dec 2016 | -$59.83 M(+7.5%) | -$13.47 M(-6.1%) | -$59.83 M(-4.7%) |
| Sep 2016 | - | -$14.35 M(-12.1%) | -$62.81 M(+1.0%) |
| Jun 2016 | - | -$16.33 M(+4.1%) | -$62.17 M(+6.6%) |
| Mar 2016 | - | -$15.68 M(-4.7%) | -$58.32 M(+4.8%) |
| Dec 2015 | -$55.67 M(+1.1%) | -$16.45 M(+20.0%) | -$55.67 M(+15.2%) |
| Sep 2015 | - | -$13.71 M(+9.8%) | -$48.34 M(+2.1%) |
| Jun 2015 | - | -$12.49 M(-4.1%) | -$47.33 M(+0.7%) |
| Mar 2015 | - | -$13.03 M(+42.8%) | -$46.99 M(-14.7%) |
| Dec 2014 | -$55.07 M(+15.3%) | -$9.12 M(-28.1%) | -$55.07 M(-8.1%) |
| Sep 2014 | - | -$12.69 M(+4.4%) | -$59.93 M(+11.6%) |
| Jun 2014 | - | -$12.15 M(-42.4%) | -$53.71 M(-13.8%) |
| Mar 2014 | - | -$21.11 M(+51.0%) | -$62.28 M(+30.4%) |
| Dec 2013 | -$47.76 M(+22.7%) | -$13.98 M(+116.0%) | -$47.76 M(+41.4%) |
| Sep 2013 | - | -$6.47 M(-68.8%) | -$33.78 M(+23.7%) |
| Jun 2013 | - | -$20.72 M(+214.8%) | -$27.31 M(+314.8%) |
| Mar 2013 | - | -$6.58 M | -$6.58 M |
| Dec 2012 | -$38.91 M(+37.0%) | - | - |
| Dec 2011 | -$28.41 M | - | - |
FAQ
- What is Revance Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Revance Therapeutics?
- What is Revance Therapeutics annual CFO year-on-year change?
- What is Revance Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Revance Therapeutics?
- What is Revance Therapeutics quarterly CFO year-on-year change?
- What is Revance Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Revance Therapeutics?
- What is Revance Therapeutics TTM CFO year-on-year change?
What is Revance Therapeutics annual cash flow from operations?
The current annual CFO of RVNC is -$216.57 M
What is the all time high annual CFO for Revance Therapeutics?
Revance Therapeutics all-time high annual cash flow from operations is -$28.41 M
What is Revance Therapeutics annual CFO year-on-year change?
Over the past year, RVNC annual cash flow from operations has changed by -$23.03 M (-11.90%)
What is Revance Therapeutics quarterly cash flow from operations?
The current quarterly CFO of RVNC is -$41.09 M
What is the all time high quarterly CFO for Revance Therapeutics?
Revance Therapeutics all-time high quarterly cash flow from operations is -$6.47 M
What is Revance Therapeutics quarterly CFO year-on-year change?
Over the past year, RVNC quarterly cash flow from operations has changed by +$9.87 M (+19.37%)
What is Revance Therapeutics TTM cash flow from operations?
The current TTM CFO of RVNC is -$190.89 M
What is the all time high TTM CFO for Revance Therapeutics?
Revance Therapeutics all-time high TTM cash flow from operations is -$6.58 M
What is Revance Therapeutics TTM CFO year-on-year change?
Over the past year, RVNC TTM cash flow from operations has changed by +$13.14 M (+6.44%)